Welcome to our dedicated page for Alector SEC filings (Ticker: ALEC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Alector, Inc. (NASDAQ: ALEC) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, sourced in real time from the U.S. Securities and Exchange Commission’s EDGAR system. Alector is a late-stage clinical biotechnology company focused on neurodegenerative diseases, and its filings offer detailed insight into clinical progress, financial performance, and corporate actions.
Investors can review Alector’s Form 8-K filings for material events such as quarterly financial results, restructuring plans, and leadership changes. For example, 8-K reports describe the announcement of second and third quarter financial results, the Phase 3 INFRONT-3 trial outcome for latozinemab (AL001) in FTD-GRN and the associated reduction in workforce, and the appointment of Neil Berkley as Chief Financial Officer while he continues as Chief Business Officer. These filings also outline estimated restructuring charges and separation arrangements for departing executives.
Beyond current reports, users can access periodic filings such as Forms 10-K and 10-Q (when available) to examine Alector’s collaboration revenue, research and development and general and administrative expenses, net loss, and cash, cash equivalents, and investment balances. For a company developing late-stage and preclinical programs in neurodegeneration, these documents are key to understanding funding runway, partnering structures, and portfolio priorities.
Stock Titan enhances these filings with AI-powered summaries that highlight the most important points in lengthy documents, helping readers quickly grasp the implications of complex disclosures. The platform also makes it easier to track insider transaction reports on Form 4 and other ownership-related filings, so users can monitor how executives and major holders interact with ALEC shares. Use this page to navigate Alector’s regulatory history, from clinical trial updates to financial and governance events, with AI tools that streamline document review.
Rosenthal Arnon reported acquisition or exercise transactions in this Form 4 filing.
Alector, Inc. chief executive officer Arnon Rosenthal reported an equity compensation grant of restricted stock units representing 116,246 shares of common stock on March 13, 2026. The RSUs were granted at no cash cost and will vest in two equal installments: one half on September 1, 2026 and one half on March 1, 2027.
Following the award, Rosenthal directly owns 2,454,422 common shares. He also reports additional indirect holdings through family trusts, including shares held by The Rosenthal Family Revocable Trust and by three 2007 trusts for family members.
Alector, Inc. reported that its CFO & Chief Business Officer, Neil Lindsay Berkley, received an equity award of 54,600 shares of Common Stock in the form of restricted stock units. These RSUs were granted at no cash cost and increase his direct holdings to 399,260 shares.
The award vests over time: one half of the RSUs will vest on September 1, 2026, and the remaining half will vest on March 1, 2027. Vesting means the units convert into unrestricted shares if the applicable service-based conditions are satisfied.
Alector, Inc. principal accounting officer Grace Wong-Sarad reported an open-market sale of 1,000 shares of common stock at $2.65 per share. The transaction took place on March 10, 2026, and she now holds 106,465 shares directly. The filing notes the sale was made under a Rule 10b5-1 trading plan adopted on September 5, 2025, indicating it was pre-scheduled rather than a discretionary trade.
Alector, Inc. has filed a shelf registration to offer up to $400,000,000 of securities, including common stock, preferred stock, debt securities, warrants, purchase contracts and units, under a prospectus dated March 12, 2026.
The prospectus is a shelf registration statement allowing multiple offerings from time to time and states that the registration includes $308,196,683.14 of unsold securities carried forward pursuant to Rule 415(a)(6) from the prior registration (File No. 333-270126). The offering will be made by prospectus supplements that set specific terms, methods of sale, and use of proceeds.
ALEC: Form 144 notice of proposed sale by Grace Wong-Sarad. The filing lists recent open-market dispositions: 3,367 Common shares sold on 03/03/2026 for $7,012.11; 8,071 Common shares sold on 03/02/2026 for $17,137.75; and 4,079 Common shares sold on 02/26/2026 for $10,197.50. The filing also lists 1,000 Restricted Stock units tied to an 03/01/2025 grant that are indicated as securities to be sold.
Alector, Inc. reported that Principal Accounting Officer Grace Wong-Sarad sold 3,367 shares of common stock in an open-market transaction. The sale occurred on March 3, 2026 at a weighted average price of $2.0826 per share, with individual sale prices ranging from $2.06 to $2.12. These transactions were made under a pre-established Rule 10b5-1 trading plan adopted on September 5, 2025. After this sale, Wong-Sarad directly owned 107,465 shares of Alector common stock.
ALEC filed a Form 144 reporting the proposed sale of 3,367 restricted common shares through Morgan Stanley Smith Barney LLC. The filing lists recent dispositions by Grace Wong-Sarad: 8,071 shares on 03/02/2026 with 17137.75, 4,079 shares on 02/26/2026 with 10197.50, and 4,753 shares on 12/05/2025 with 5751.13.
Alector, Inc. Principal Accounting Officer Grace Wong-Sarad reported an open-market sale of 8,071 shares of common stock. The weighted average sale price was $2.1234 per share, with individual trades executed between $2.04 and $2.37 per share.
According to the disclosure, the shares were sold to satisfy the reporting person's tax obligations arising from the vesting of restricted stock units. After this transaction, the officer directly owned 110,832 shares of Alector common stock.
Alector, Inc. Chief Executive Officer Arnon Rosenthal reported an open-market sale of 81,864 shares of common stock on March 2, 2026 at a weighted average price of $2.1233 per share. According to the footnotes, the shares were sold to satisfy his tax obligations arising from the vesting of restricted stock units.
After this sale, Rosenthal directly owns 2,338,176 shares of Alector common stock. He also has indirect holdings through family trusts, including 1,972,875 shares held by The Rosenthal Family Revocable Trust and 652,500 shares each held by the Adi Rosenthal 2007 Trust, the Noam Rosenthal 2007 Trust, and the Shani Rosenthal 2007 Trust, for which he serves as trustee.
Alector, Inc. executive Neil Lindsay Berkley, the CFO and Chief Business Officer, reported an open-market sale of common stock. He sold 29,649 shares on March 2, 2026 at a weighted average price of $2.1233 per share to cover tax obligations from vesting RSUs. After this transaction, he continued to hold 344,660 shares of Alector common stock directly.